Johnson & Johnson $JNJ Stake Boosted by IFG Advisory LLC

IFG Advisory LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.5% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 41,755 shares of the company’s stock after purchasing an additional 2,177 shares during the period. IFG Advisory LLC’s holdings in Johnson & Johnson were worth $11,054,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. National Pension Service increased its stake in shares of Johnson & Johnson by 1.3% during the second quarter. National Pension Service now owns 5,226,968 shares of the company’s stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the period. IFP Advisors Inc boosted its stake in Johnson & Johnson by 8.8% in the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company’s stock valued at $9,844,000 after purchasing an additional 3,133 shares during the period. Elefante Mark B boosted its stake in Johnson & Johnson by 9.8% in the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company’s stock valued at $7,285,000 after purchasing an additional 2,563 shares during the period. AMG Asset Management Group Inc. boosted its stake in Johnson & Johnson by 172.0% in the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company’s stock valued at $1,020,000 after purchasing an additional 2,436 shares during the period. Finally, Gradient Investments LLC grew its holdings in Johnson & Johnson by 9.9% in the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company’s stock valued at $38,815,000 after buying an additional 13,737 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Key Stories Impacting Johnson & Johnson

These are some of the JNJ stories that stood out recently:

• Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The notice provides no specific findings, but litigation-related uncertainty may weigh on sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Johnson & Johnson Investors

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on JNJ shares. Morgan Stanley lowered their price objective on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research report on Thursday, October 15th. Johnson Rice cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Sanford C. Bernstein set a $270.00 price target on shares of Johnson & Johnson in a research note on Thursday, October 15th. Guggenheim reaffirmed a “buy” rating and set a $287.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Finally, Argus set a $300.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $275.92.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded up $2.26 during mid-day trading on Friday, reaching $285.78. 6,279,519 shares of the company were exchanged, compared to its average volume of 7,472,752. The company has a fifty day simple moving average of $266.97 and a 200-day simple moving average of $249.85. Johnson & Johnson has a 12 month low of $193.55 and a 12 month high of $288.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The firm has a market cap of $687.95 billion, a PE ratio of 43.30, a PEG ratio of 2.80 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s payout ratio is 81.21%.

Insider Buying and Selling

In related news, EVP Elizabeth Forminard sold 13,072 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,669 shares of company stock valued at $16,898,386 over the last quarter. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.